Trials / Unknown
UnknownNCT01312337
Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)
A Phase II Trial of Gefitinib Monotherapy in Pretreated Patients With Advanced Non-small Cell Lung Cancer Not Harboring Active EGFR Mutations
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 92 (estimated)
- Sponsor
- Samsung Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators will examine efficacy and toxicity of gefitinib in Korean patients with EGFR wild tumors diagnosed with direct sequence test.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | salvage iressa | Iressa 250mg per day until progression |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2012-08-01
- First posted
- 2011-03-10
- Last updated
- 2011-03-10
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01312337. Inclusion in this directory is not an endorsement.